Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

  • Filters activated: Cancer. Clear all to show 92 items.
1.

Pharmacokinetics of orbifloxacin in crucian carp (Carassius auratus) after intravenous and intramuscular administration.

Yang F, Yang F, Wang G, Shi W, Kong T, Yang P, Bai D, Zhou B.

J Vet Pharmacol Ther. 2018 Aug;41(4):599-604. doi: 10.1111/jvp.12495. Epub 2018 Feb 21.

PMID:
29465160
2.

Development of a multiroute physiologically based pharmacokinetic model for orbifloxacin in rabbits.

Yang F, Yang F, Shi W, Si H, Kong T, Wang G, Zhang J.

J Vet Pharmacol Ther. 2018 Aug;41(4):622-631. doi: 10.1111/jvp.12496. Epub 2018 Feb 18.

PMID:
29457247
3.

Assessment of urinary pharmacokinetics and pharmacodynamics of orbifloxacin in healthy dogs with ex vivo modelling.

Shimizu T, Harada K, Manabe S, Tsukamoto T, Ito N, Hikasa Y.

J Med Microbiol. 2017 May;66(5):616-621. doi: 10.1099/jmm.0.000476. Epub 2017 May 4.

PMID:
28470147
4.
5.
6.

What Is Your Diagnosis? Fungal pneumonia and aspergillosis.

Greenbarg EH, Secrest SA.

J Am Vet Med Assoc. 2016 May 1;248(9):999-1001. doi: 10.2460/javma.248.9.999. No abstract available.

PMID:
27074606
7.

Structure, Solubility and Stability of Orbifloxacin Crystal Forms: Hemihydrate versus Anhydrate.

Santos OM, Freitas JT, Cazedey EC, de Araújo MB, Doriguetto AC.

Molecules. 2016 Mar 9;21(3):328. doi: 10.3390/molecules21030328.

8.

Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus).

Watson MK, Wittenburg LA, Bui CT, Jarosz KA, Gustafson DL, Johnston MS.

Am J Vet Res. 2015 Nov;76(11):946-51. doi: 10.2460/ajvr.76.11.946.

PMID:
26512539
9.

Effects of oral orbifloxacin on fecal coliforms in healthy cats: a pilot study.

Harada K, Sasaki A, Shimizu T.

J Vet Med Sci. 2016 Jan;78(1):83-9. doi: 10.1292/jvms.15-0407. Epub 2015 Aug 27.

11.
12.

Assessment of synergistic interactions of danofloxacin and orbifloxacin against quinolone-resistant Escherichia coli isolated from animals by the checkerboard and time-kill methods.

Cengiz M, Sahinturk P.

J Antibiot (Tokyo). 2013 Oct;66(10):629-31. doi: 10.1038/ja.2013.62. Epub 2013 Jun 19. No abstract available.

PMID:
23778116
13.
14.

Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration.

Dudhatra GB, Kumar A, Awale MM, Kamani DR, Chauhan BN, Patel HB, Mody SK.

J Pharmacol Toxicol Methods. 2013 Jan-Feb;67(1):50-3. doi: 10.1016/j.vascn.2012.11.002. Epub 2012 Dec 8.

PMID:
23231925
15.

Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs.

Harada K, Shimizu T, Kataoka Y, Takahashi T.

Acta Vet Scand. 2012 Mar 20;54:16. doi: 10.1186/1751-0147-54-16.

16.

Complications from residual adnexal structures following enucleation in three dogs.

Ward AA, Neaderland MH.

J Am Vet Med Assoc. 2011 Dec 15;239(12):1580-3. doi: 10.2460/javma.239.12.1580.

PMID:
22129122
17.

Comparative pharmacokinetics of orbifloxacin in healthy and Pasteurella multocida infected ducks.

Tohamy MA.

Br Poult Sci. 2011 Oct;52(5):639-44. doi: 10.1080/00071668.2011.616953.

PMID:
22029792
18.

Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs.

Gebru E, Damte D, Choi MJ, Lee SJ, Kim YH, Park SC.

Vet Microbiol. 2012 Jan 27;154(3-4):384-94. doi: 10.1016/j.vetmic.2011.07.033. Epub 2011 Aug 6.

PMID:
21893387
19.

Allometric scaling of orbifloxacin disposition in nine mammal species: a retrospective analysis.

Gebru E, Lee SJ, Kim JC, Park SC.

J Vet Med Sci. 2011 Jun;73(6):817-20. Epub 2011 Jan 12.

20.

Short communication: Fluoroquinolone susceptibility of Staphylococcus aureus strains isolated from caprine clinical mastitis in southeast Spain.

Marín P, Escudero E, Fernández-Varón E, Cárceles CM, Corrales JC, Gómez-Martín A, Martínez I.

J Dairy Sci. 2010 Nov;93(11):5243-5. doi: 10.3168/jds.2010-3345.

Supplemental Content

Loading ...
Support Center